Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. openmedicine

openMedicine

openMedicine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 openMedicine project word cloud

Explore the words cloud of the openMedicine project. It provides you a very rough idea of what is the project "openMedicine" about.

investigates    wp5    abroad    communication    mp    ms    sdos    solved    pharmacological    phc34    gs1    epsos    stage    professionals    wp1    duty    experts    explores    pharmacokinetic    wp3    industry    agencies    economic    assure    wps    cross    post    trust    regulatory    framework    issue    univocal    policy    road    track    clinical    options    efforts    ema    meta    message    beneficiaries    mss    team    health    wp4    concise    innovation    network    workshops    idmp    respect    cen    transfer    considering    unambiguous    situation    identification    usa    ehealth    harmonise    attributes    lasts    standards    map    dispensed    patients    substitution    stakeholders    acceptance    practicability    develops    conceptual    healthcare    medicinal    border    description    link    models    mou    meetings    recommendations    roadmap    hl7    definition    csa    validated    data    prescribed    competent    vocabulary    risks    f2f    indications    pharmaceutical    implementations    expanding    expert    safety    eprescriptions    solutions    national    therapeutic    iso    serious    25    actions    core    mapping    mps    ihtsdo    practices    scenarios    interoperable    implementability    encountered    global    rules   

Project "openMedicine" data sheet

The following table provides information about the project.

Coordinator		 EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH 

Organization address
address: OXFORDSTRASSE 2
city: BONN
postcode: 53111
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.open-medicine.eu
 Total cost 997˙938 €
 EC max contribution 997˙938 € (100%)
 Programme 1. H2020-EU.3.1.5. (Methods and data)
 Code Call H2020-PHC-2014-single-stage
 Funding Scheme CSA
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH DE (BONN) coordinator 191˙875.00
2    CUSTODIX NV BE (SINT-MARTENS-LATEM) participant 299˙625.00
3    HEALTH PRODUCTS REGULATORY AUTHORITY IE (DUBLIN) participant 110˙625.00
4    HL7 INTERNATIONAL FONDATION BE (BRUSSELS) participant 90˙313.00
5    SIEC BADAWCZA LUKASIEWICZ INSTYTUTLOGISTYKI I MAGAZYNOWANIA PL (POZNAN) participant 87˙625.00
6    REGIONE LOMBARDIA IT (MILANO) participant 80˙625.00
7    AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS ES (MADRID) participant 74˙375.00
8    STICHTING KONINKLIJK NEDERLANDS NORMALISATIE INSTITUUT NL (DELFT) participant 62˙875.00

Map

 Project objective

The CSA will enhance the safety of cross-border healthcare through interoperable ePrescriptions. epSOS solved the message transfer problem, but encountered 2 serious “delivery” problems: the univocal identification of medicinal products (MPs) dispensed abroad, and substitution challenges. Global SDOs (WHO, HL7, IHTSDO, ISO/CEN, GS1), EU regulatory agencies (EMA), MS Competent Authorities, major stakeholders (industry, health professionals, patients) harmonise their related efforts to deliver • common data models - expanding upon epSOS and existing standards (ISO/IDMP) - for prescribed MPs • a common meta-vocabulary for unambiguous definition, description, and identification of MPs • rules to harmonise practices of therapeutic and economic substitution • a roadmap for post-project actions and implementations • policy recommendations for the EU-USA road mapping process (MoU) Work will link to related research & innovation activities of SDOs, epSOS, policy and regulatory processes (eHealth Network), the three other PHC34 projects. WP1 develops a concise conceptual framework, including use case scenarios where the identification of a MP is an issue, including pharmacological and pharmacokinetic attributes, clinical indications and risks. WPs 2 address the identification and description of the pharmaceutical products, considering implementability as essential. WP3 investigates the situation in MSs with respect to substitution, and explores options for substitution. Each track develops a set of concrete solutions and road map recommendations, validated by experts in F2F meetings and workshops in WP4. Fostering exploitation by MS regulatory agencies and communication of results is the duty of WP5. The project involves national competent authorities, SDOs and stakeholders not part of the core team at an early stage to assure the practicability, acceptance and trust in the solutions developed. The CSA lasts 2 years involving 8 beneficiaries and about 25 expert organisations.

 Deliverables

List of deliverables.
D6.1 1st annual report on the activities of the Expert Council Documents, reports 2019-07-23 09:11:13
D2.1 Report on standards based identification and description enabling dispensing equivalent medicinal products Documents, reports 2019-07-23 09:11:14
D1.2 Complementary uses cases Documents, reports 2019-07-23 09:11:14
D1.1 epSOS identification/description problems Documents, reports 2019-07-23 09:11:14
D2.3 openMedicine final identifying and descriptive attributes Documents, reports 2019-07-23 09:11:14
D8.2 openMedicine portal online Websites, patent fillings, videos etc. 2019-07-23 09:11:14
D5.2 openMedicine substitution: options and roadmap Documents, reports 2019-07-23 09:11:13
D5.1 Meeting the substitution challenge: Member State regulations and core cross-border issues Documents, reports 2019-07-23 09:11:13
D7.1 Communication Plan Documents, reports 2019-07-23 09:11:13
D6.2 Report on validation activities Documents, reports 2019-07-23 09:11:13
D1.3 Initial openMedicine infostructure Documents, reports 2019-07-23 09:11:14
D7.2 1st Communication and Liaison Report Documents, reports 2019-07-23 09:11:14
D7.3 2nd Communication and Liaison Report Documents, reports 2019-07-23 09:11:14
D6.4 2nd annual report on the activities of the Expert Council Documents, reports 2019-07-23 09:11:14
D6.3 openMedicine Recommendations and Roadmap for Implementation Documents, reports 2019-07-23 09:11:13
D2.2 Comprehensive set of openMedicine identifying and descriptive attributes of medicinal products and the available standards Documents, reports 2019-07-23 09:11:14

Take a look to the deliverables list in detail:  detailed list of openMedicine deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPENMEDICINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPENMEDICINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

Read More  

iReceptor Plus (2019)

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T-CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY

Read More  

CINECA (2019)

Common Infrastructure for National Cohorts in Europe, Canada, and Africa

Read More